NLRP3炎症小体在神经退行性疾病及其治疗中的作用研究进展

doi:10.19803/j.1672-8629.20230154

摘要/Abstract

摘要： 神经退行性疾病是全球老龄化人口面临的一个重要健康问题,患者通常表现为认知下降、运动功能丧失以及痴呆等症状。神经退行性疾病的发病机制较为复杂,目前针对该类疾病的治疗只能控制其症状。NLRP3炎症小体作为研究最多的炎症小体在神经退行性疾病中广泛参与。本综述对NLRP3炎症小体的结构与功能及其在不同神经退行性疾病中的参与进行总结,并介绍了目前在神经退行性疾病的治疗中,以NLRP3炎症小体为靶点的治疗及药物研究进展。

关键词: NLRP3炎症小体, 神经退行性疾病, 帕金森病, 阿尔兹海默症

Abstract: Neurodegenerative diseases are serious health issues facing the world’s aging population, which are usually manifested as cognitive decline, loss of motor function and dementia. The pathogenesis of neurodegenerative diseases is complex, and current treatments for these diseases can do nothing more than control their symptoms. NLRP3 inflammasome, as the most studied inflammasome, is widely involved in neurodegenerative diseases. This article reviews the structure and function of NLRP3 inflammasome and its involvement in different neurodegenerative diseases before the progress in drug research related NLRP3 inflammasome in the treatment of neurodegenerative diseases is summarized.

Key words: NLRP3 inflammasome, neurodegenerative disease, Parkinson’s disease, Alzheimer’s disease

中图分类号:

R971
R744

马一丹, 沈鑫, 杨珺, 闫加庆. NLRP3炎症小体在神经退行性疾病及其治疗中的作用研究进展[J]. 中国药物警戒, 2023, 20(11): 1316-1320.

MA Yidan, SHEN Xin, YANG Jun, YAN Jiaqing. Research progress in the role of NLRP3 inflammasome in neurodegenerative diseases and in treat-ments[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1316-1320.

参考文献

[1] GUPTA SP.Advances in studies on neurodegenerative diseases and their treatments[J]. Curr Top Med Chem, 2020, 20(13): 2379.
[2] KHANAM H, ALI A, ASIF M, et al.Neurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: a review[J]. Eur J Med Chem, 2016, 124(29): 1121-1141.
[3] SWANSON KV, DENG M, TING JP.The NLRP3 inflammasome: molecular activation and regulation to therapeutics[J]. Nat Rev Immunol, 2019, 19(8): 477-489.
[4] SHASTRI A, BONIFATI DM, KISHORE U.Innate immunity and neuroinflammation[J]. Mediators Inflamm, 2013, 2013: 342931.
[5] FULLARD N, O’REILLY S. Role of innate immune system in systemic sclerosis[J]. Semin Immunopathol, 2015, 37(5): 511-517.
[6] LAMKANI M, DIXIT VM.In retrospect: the inflammasome turns 15[J]. Nature, 2017, 548(7669): 534-535.
[7] MANGAN MSJ, OLHAVA EJ, ROUSH WR, et al.Targeting the NLRP3 inflammasome in inflammatory diseases[J]. Nat Rev Drug Discov, 2018, 17(9): 688.
[8] SCHRODER K, TSCHOPP J.The inflammasomes[J]. Cell, 2010, 140: 821-832.
[9] MINKIEWICZ J, DE RIVERO VACCARI JP, KEANE RW. Human astrocytes express a novel NLRP2 inflammasome[J]. Glia, 2013, 61(7): 1113-1121.
[10] WANG S, CHEN NH, YUAN YH.Advances in research on targeted treatment of Alzheimer’s disease[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(12): 755-760.
[11] DUNCAN JA, BERGSTRALH DT, WANG Y, et al.Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling[J]. Proc Natl Acad Sci USA, 2007, 104(19): 8041-8046.
[12] BAI H, ZHANG Q.Activation of NLRP3 inflammasome and onset of Alzheimer’s disease[J]. Front Immunol, 2021, 12: 701282.
[13] WANG Y, LIU X, SHI H, et al.NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases[J]. Clin Transl Med, 2020, 10(1): 91-106.
[14] WANG Z, ZHANG S, XIAO Y, et al.NLRP3 inflammasome and inflammatory diseases[J]. Oxid Med Cell Longev, 2020, 2020: 4063562.
[15] ANAND R, GILL KD, MAHDI AA.Therapeutics of Alzheimer’s disease: past, present and future[J]. Neuropharmacology, 2014, 76(PtA): 27-50.
[16] HALLE A, HORNUNG V, PETZOLD GC, et al.The NALP3 inflammasome is involved in the innate immune response to amyloid-beta[J]. Nat Immunol, 2008, 9(8): 857-865.
[17] TARKOWSKI E.Intrathecal inflammation precedes development of Alzheimer’s disease[J]. J Neurol Neurosurg Psychiatry, 2003, 74(9): 1200-1205.
[18] WRIGHT AL, ZINN R, HOHENAINN B, et al.Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease[J]. PLoS One, 2013, 8(4): e59586.
[19] ZHU SG, SHENG JG, JONES RA, et al.Increased interleukin-1beta converting enzyme expression and activity in Alzheimer disease[J]. J Neuropathol Exp Neurol, 1999, 58: 582-587.
[20] VENEGAS C, KUMAR S, FRANKLIN BS, et al.Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease[J]. Nature, 2017, 552: 355-361.
[21] JU YE, LUCEY BP, HOLTZMAN DM.Sleep and Alzheimer disease pathology-a bidirectional relationship[J]. Nat Rev Neurol, 2014, 10(2): 115-119.
[22] KRABBE G, HALLE A, MATYASH V, et al.Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology[J]. PLoS One, 2013, 8: e60921.
[23] ISING C, VENEGAS C, ZHANG S, et al.NLRP3 inflammasome activation drives tau pathology[J]. Nature, 2019, 575: 669-673.
[24] POEWE W, SEPPI K, TANNER CM, et al.Parkinson disease[J]. Nat Rev Dis Primers, 2017, 3: 17013.
[25] DAUER W, PRZEDBORSKI S.Parkinson’s disease: mechanisms and models[J]. Neuron, 2003, 39(6): 889-909.
[26] HIRSCH EC, HUNOT S.Neuroinflammation in Parkinson’s disease: a target for neuroprotection[J]. Lancet Neurol, 2009, 8(4): 382-397.
[27] OLANOW CW, SAVOLAINEN M, CHU Y, et al.Temporal evolution of microglia and alpha-synuclein accumulation following foetal grafting in Parkinson’s disease[J]. Brain, 2019, 142: 1690-1700.
[28] HARMS AS, DELIC V, THOME AD, et al.A-synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration[J]. Acta Neuropathol Commun, 2017, 5: 85.
[29] CROISIER E, MORAN LB, DEXTER DT, et al.Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition[J]. J Neuroinflammation, 2005, 2: 14.
[30] BAUERNFEIND FG, HORVATH G, STUTZ A, et al.Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression[J]. J Immunol, 2009, 183(2): 787-791.
[31] BLOCK ML, ZECCA L, HONG JS.Microglia-mediated neurotoxicity: uncovering the molecular mechanisms[J]. Nat Rev Neurosci, 2007, 8(1): 57-69.
[32] FERRARI CC, POTT GODOY MC, TARELLI R,et al.Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra[J]. Neurobiol Dis, 2006, 24(1): 183193.
[33] YAN Y, JIANG W, LIU L, et al.Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome[J]. Cell, 2015, 160(1-2): 62-73.
[34] TSCHOPP J.MITOCHONDRIA: sovereign of inflammation[J]. Eur J Immunol, 2011, 41(5): 1196-1202.
[35] NAKAHIRA K, HASPEL JA, RATHINAM VA, et al.Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome[J]. Nat Immunol, 2011, 12(3): 222-230.
[36] YOULE RJ, NARENDRA DP.Mechanisms of mitophagy[J]. Nat Rev Mol Cell Biol, 2011, 12(1): 9-14.
[37] MANGIARINI L, SATHASIVAM K, SELLER M, et al.Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice[J]. Cell, 1996, 87(3): 493-506.
[38] WILSON RS, COMO PG, GARRON DC, et al.Memory failure in Huntington’s disease[J]. J Clin Exp Neuropsychol, 1987, 9(2):147-154.
[39] WALKER FO.Huntington’s disease[J]. Lancet, 2007, 369(9557): 218-228.
[40] GLINSKY GV.SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways[J]. Cell Cycle, 2008, 7(22): 3564-3576.
[41] BJORKQVIST M, WILD EJ, THIELE J, et al.A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease[J]. J Exp Med, 2008, 205(8): 1869-1877.
[42] ONA VO, LI M, VONSATTEL JP, et al.Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease[J]. Nature, 1999, 399(6733): 263-267.
[43] SIEW JJ, CHEN HM, CHEN HY, et al.Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease[J]. Nat Commun, 2019, 10(1): 3473.
[44] COMPSTON A, COLES A.Multiple sclerosis[J]. Lancet, 2008, 372(9648): 1502-1517.
[45] BEYNON V, QUINTANA FJ, WEINER HL.Activated human CD4 + CD45RO + memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling[J]. PLoS One, 2012, 7: e39576
[46] SOARES JL, OLIVEIRA EM, PONTILLO A.Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis[J]. Mult Scler Relat Disord, 2019, 29: 26-34.
[47] VOET S, MC GUIRE C, HAGEMEYER N, et al.A20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation[J]. Nat Commun, 2018, 9(1): 2036.
[48] MCKENZIE B, REINKE S, BRANTON W, et al.Activation of multiple inflammasomes within the central nervous system during experimental autoimmune encephalomyelitis and multiple sclerosis[J]. Journal of Neuroimmunology, 2014, 275(1-2): 163.
[49] KEANE RW, DIETRICH WD, DE RIVERO VACCARI JP. Inflammasome proteins as biomarkers of multiple sclerosis[J]. Front Neurol, 2018, 9: 135.
[50] LEE JD, KUMAR V, FUNG JN, et al.Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1^G93A mouse model of amyotrophic lateral sclerosis[J]. Br J Pharmacol, 2017, 174(8): 689-699.
[51] HARDIMANO, VAN DEN BERG LH, KIERNAN MC. Clinical diagnosis and management of amyotrophic lateral sclerosis[J]. Nat Rev Neurol, 2011, 7(11): 639-649.
[52] MORGAN S, ORRELL RW.Pathogenesis of amyotrophic lateral sclerosis[J]. British Medical Bulletin, 2016, 119(1): 87-98.
[53] ROSEN DR.Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis[J]. Nature, 1993, 364(6435): 362.
[54] ALEXIANU ME, KOZOVSKA M, APPEL SH.Immune reactivity in a mouse model of familial ALS correlates with disease progression[J]. Neurology, 2001, 57(7): 1282-1289.
[55] GUGLIANDOLO A, GIACOPPO S, BRAMANTI P, et al.NLRP3 inflammasome activation in a transgenic amyotrophic lateral sclerosis model[J]. Inflammation, 2018, 41(1): 93-103.
[56] COLL RC, ROBERTSON AA, CHAE JJ, et al.A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases[J]. Nat Med, 2015, 21(3): 248-255.
[57] YIN J, ZHAO F, CHOJNACKI JE, et al.NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer’s disease[J]. Mol Neurobiol, 2018, 55(3): 1977-1987.
[58] FLORES J, NOEL A, FOVEAU B, et al.Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model[J]. Nat Commun, 2018, 9(1): 3916.
[59] KUEMMERLE-DESCHNER JB, HACHULLA E, CARTWRIGHT R, et al.Twoyear results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes[J]. Ann Rheum Dis, 2011, 70(12): 2095-2102.
[60] DANIELS MJ, RIVERS-AUTY J, SCHILLING T, et al.Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models[J]. Nat Commun, 2016, 11(7): 12504.
[61] RANGASAMY SB, DASARATHI S, PAHAN P, et al.Low-dose aspirin upregulates tyrosine hydroxylase and increases dopamine production in dopaminergic neurons: implications for Parkinson’s disease[J]. J Neuroimmune Pharmacol, 2019, 14(2): 173-187.